𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Verbal repetition in patients with Alzheimer's disease who receive donepezil

✍ Scribed by Elissa Asp; France Cloutier; Sherri Fay; Cheryl Cook; Mary Lou Robertson; John Fisk; Ding-Wai Dei; Kenneth Rockwood


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
96 KB
Volume
21
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis


Background:

Current outcome measures for alzheimer's disease (ad) drugs have been criticized as insufficiently patient-centred. one commonly unmeasured goal of patients and caregivers is verbal repetition.

Objectives:

We examined how often reducing repetition (of questions, statements or stories) was set as treatment goal, whether and when it responded, and how change in repetition correlated with change in other domains.

Methods:

This is a secondary analysis of the open-label atlantic canada alzheimer's disease investigation of expectations study of donepezil for mild-moderate ad in 100 community-dwelling people. goal attainment scaling, an individualized account of the goals of treatment, was the primary outcome measure.

Results:

Reducing repetition was a treatment goal in 46%, who were not systematically different from others. of 18 patients in whom repetition improved for 9 months, 83% (15) showed a response at 3 months. early (3-month) response correlated best with the overall level of goal attainment (r = 0.74) and changes in leisure activities (r = 0.69) and social interactions (r = 0.68) compared with changes in cognition (r = 0.44) or behaviour (r = 0.11). correlations with the adas-cog and mmse change scores remained only modest (at 12 months = -0.25 and 0.19, respectively). correlations with the cibic-plus were higher (-0.47 at 3 months and -0.43 at 12 months).

Conclusion:

Diminution of repetition is common, and appears to mark response to cholinesterase inhibition in some patients. responders generally also show improved cognition and function, perhaps as an aspect of improved executive function.


πŸ“œ SIMILAR VOLUMES


Preliminary communication: Urodynamic as
✍ Ryuji Sakakibara; Tomoyuki Uchiyama; Mitsuharu Yoshiyama; Tomoyuki Yamanishi; Ta πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 113 KB

## Abstract ## Background and Aims Donepezil hydrochloride, a central cholinergic drug, is widely used for improving cognitive decline in Alzheimer's disease (AD). We investigated whether donepezil might affect the lower urinary tract (LUT) function in AD. ## Methods Alzheimer's Disease Assessme

Tolerability of switching from donepezil
✍ Gunhild Waldemar; Maritta HyvΓ€rinen; Mette Krog Josiassen; Alex KΓΈrner; Heikki L πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 44 KB πŸ‘ 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Depressive symptoms in patients with Alz
✍ Nitin Purandare; Alistair Burns; Sarah Craig; Brian Faragher; Kathy Scott πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 2 views

## Abstract ## Objectives A comparison was made between the depressive symptom profiles of thirty patients with Alzheimer's disease (AD) who did not have co‐existing depression and thirty patients with major depression who did not have co‐existing dementia. The main objective was to identify sympt